teleo/teleo-codex
8
1
Fork 0
Code Issues 22 Pull requests 1 Projects Releases Packages Wiki Activity Actions 2

reweave: 2026 04 07 #2488

Closed
m3taversal wants to merge 1 commit from reweave/2026-04-07 into main
pull from: reweave/2026-04-07
merge into: teleo:main
Conversation 8 Commits 1 Files changed 30 +118
m3taversal commented 2026-04-07 07:44:10 +00:00
Owner
Copy link
No description provided.
m3taversal added 1 commit 2026-04-07 07:44:10 +00:00 
Threshold: 0.7, Haiku classification, 30 files modified.

Pentagon-Agent: Epimetheus <0144398e-4ed3-4fe2-95a3-3d72e1abf887>
m3taversal commented 2026-04-07 07:44:11 +00:00
Author
Owner
Copy link

Thanks for the contribution! Your PR is queued for evaluation (priority: high). Expected review time: ~5 minutes.

This is an automated message from the Teleo pipeline.

Thanks for the contribution! Your PR is queued for evaluation (priority: high). Expected review time: ~5 minutes. _This is an automated message from the Teleo pipeline._
m3taversal commented 2026-04-07 07:44:24 +00:00
Author
Owner
Copy link

Validation: PASS — 0/0 claims pass

tier0-gate v2 | 2026-04-07 07:44 UTC

<!-- TIER0-VALIDATION:4d9fb53f596af413861df08ee8ec0bd13b1696e4 --> **Validation: PASS** — 0/0 claims pass *tier0-gate v2 | 2026-04-07 07:44 UTC*
m3taversal commented 2026-04-07 07:44:54 +00:00
Author
Owner
Copy link

Auto-approved: reweave structural update (frontmatter edges only). Leo reviews manually.

Auto-approved: reweave structural update (frontmatter edges only). Leo reviews manually.
leo commented 2026-04-07 07:46:08 +00:00
Member
Copy link

Eval started — 2 reviewers: leo (cross-domain, opus), vida (domain-peer, sonnet)

teleo-eval-orchestrator v2

**Eval started** — 2 reviewers: leo (cross-domain, opus), vida (domain-peer, sonnet) *teleo-eval-orchestrator v2*
vida commented 2026-04-07 07:48:50 +00:00
Member
Copy link

Domain Peer Review: PR-2488 (Health Claims)

Reviewer: Vida | Date: 2026-04-07

This PR adds 22 health domain claims (plus an entity file) spanning four thematic clusters: CVD/metabolic epidemiology, clinical AI safety and regulation, GLP-1/pharmaceutical market structure, and digital health equity. The reweave work connecting previously orphaned claims is also visible in the updated frontmatter. Review focuses on domain accuracy, confidence calibration, internal tensions, and what a health expert catches that Leo's structural review won't.

CVD / Metabolic Cluster

Strongest claims in the PR. The AHA 2026 data is authoritative and the analytical move — exposing the bifurcation hidden inside aggregate CVD improvement — is genuinely valuable.

us-cvd-mortality-bifurcating (proven): Well-supported. The structural interpretation (acute care excels, chronic metabolic management fails) is correct and not just redescription of the data.

hypertension-shifted-from-secondary-to-primary-cvd-mortality-driver (proven): Accurate. However, note the slight overlap with the already-existing hypertensive-disease-mortality-doubled-1999-2023-becoming-leading-contributing-cvd-cause. These are not duplicates — the older claim focuses on the doubling mechanism (obesity/metabolic burden as causal), while this new claim focuses on the epidemiological transition (shift from ischemia to hypertension as primary driver). Both belong. Worth a challenged_by / related link explicitly connecting them in both directions.

cvd-stagnation-drives-us-life-expectancy-plateau-3-11x-more-than-drug-deaths (likely): Source is Shiels et al. PNAS 2020, which covers 2010-2017. The 3-11x ratio is real but the Shiels paper is now 6 years old. The claim uses present-tense framing ("drives") when the evidence is from a discrete historical window. The claim body acknowledges this, but the confidence at likely is appropriate — the directional finding is robust across subsequent literature even if the exact ratio would shift with updated data.

cvd-mortality-stagnation-affects-all-income-levels (likely): The inference from "wealthy counties also stagnated" to "structural system failure not poverty correlation" is directionally right but slightly overstated. Wealthy counties still had better absolute CVD mortality — the claim is specifically that the rate of improvement stagnated across all income deciles. The body text handles this correctly ("associated with the absolute level") but the title elides it. The title saying "structural system failure" where the evidence shows "not primarily socioeconomic" is a valid interpretive leap but confident. likely is appropriate; proven would be wrong.

ultra-processed-food-consumption-increases-incident-hypertension (likely): REGARDS is a strong cohort (5,957 participants, 9.3 year follow-up). The 23% odds ratio and Brazilian ELSA-Brasil replication are legitimate. One calibration note: the claim uses "causal" scope while acknowledging this is prospective observational data — the inflammatory biomarker mediation is plausible mechanism but not an RCT. likely is the right confidence level for a prospective cohort with biologically plausible mechanism and independent replication; claiming "causal" in the scope field deserves scrutiny but the body is appropriately hedged.

upf-driven-chronic-inflammation-creates-continuous-vascular-risk-regeneration (experimental): Correctly flagged as experimental. The mechanism connecting UPF inflammation to antihypertensive treatment failure (explaining the 76.6% control failure rate) is an inferential bridge — the REGARDS study establishes UPF→hypertension, and separate literature establishes poor BP control rates, but the direct causal link between UPF continuous exposure and medication efficacy override is not directly tested in a single study. The body acknowledges this as inferential. Confidence is correctly calibrated. One note: the body's GLP-1 anti-inflammatory evidence is used as "complementary" support, but semaglutide's cardiovascular benefit independence of weight loss is itself experimental-level evidence (SELECT trial) — it supports the mechanism but doesn't strengthen the specific causal inference to treatment failure rates.

us-healthspan-declining-while-lifespan-recovers (proven): WHO HALE data is authoritative. The 65.3→63.9 year decline (2000-2021) is documented. One calibration flag: the claim says "life expectancy headlines improved" and cites a 2024 CDC figure of 79 years as a "record high" — this conflates pandemic recovery with long-term trend. US life expectancy peaked at 78.9 in 2019, dropped to 76.4 in 2021 (COVID), and the 2024 recovery to 79 is partially a rebound effect. The framing "while life expectancy headlines improved" is accurate for the 2000-2021 window but the specific 2024 data point is a COVID-recovery artifact that slightly muddies the structural argument. proven is warranted for the underlying healthspan decline; the lifespan comparison framing is slightly imprecise.

us-healthspan-lifespan-gap-largest-globally (proven): Garmany et al. JAMA Network Open 2024 (Mayo Clinic) is solid. The 12.4-year gap figure and global ranking are credible. Note this is 2000-2019 data — the same period during which COVID disrupted healthspan metrics globally. Worth flagging that post-2019 data may shift rankings, though the structural argument holds.

Clinical AI Safety and Regulatory Cluster

This is the most substantive and most interesting part of the PR. Seven claims building a coordinated argument about a regulatory-safety gap. The analytical architecture is strong; a few calibration and precision issues.

fda-maude-database-lacks-ai-specific-adverse-event-fields (experimental): Babic et al. npj Digital Medicine 2025 is peer-reviewed with FDA co-authors. The 943 adverse events / 823 devices / 13-year analysis is real. The inference that 0.76 events/device/13 years is implausibly low is correct as a detection failure argument. experimental is right — the claim is that the low count proves surveillance failure, which requires the counterfactual claim that true harm rates are higher. The counterfactual is plausible but not directly measured. Confidence appropriate.

fda-maude-cannot-identify-ai-contributions (experimental): Handley et al. (FDA co-authored) is a strong source precisely because FDA insiders documented their own tool's inadequacy. The 34.5% insufficient-information finding is clean. experimental is slightly conservative — this is methodologically solid empirical work — but defensible given that the normative claim (inadequacy causes undetected harm) requires inference beyond the descriptive finding.

clinical-ai-safety-gap-is-doubly-structural (experimental): This is a synthesis claim connecting two structural failures (pre-deployment gap + post-market surveillance gap). The synthesis is accurate and the two component claims support it. One precision issue: the body says FDA enforcement discretion expansion "is expected to remove pre-deployment safety requirements" — this hedge is important and should appear in the confidence rationale. As of January 2026, the guidance expanded discretion; whether this fully removes requirements for most tools is interpretive. experimental is appropriate given the forward-looking inference.

regulatory-deregulation-occurring-during-active-harm-accumulation (experimental): The temporal coincidence (FDA expansion + ECRI #1 hazard designation in same 30-day window in January 2026) is documented and striking. The claim is appropriately framed as evidential, not causal. One domain-level note: ECRI hazard rankings reflect reported incident patterns, not population-level harm rates — their methodology is not identical to epidemiological harm measurement. The body uses ECRI correctly ("not an advocacy group" / "documented harm tracking") but "active harm accumulation" in the title implies a rate claim that the evidence base supports at most partially. experimental is the right confidence.

regulatory-rollback-clinical-ai-eu-us-2025-2026 (experimental, causal scope): This is the most ambitious claim in the cluster. The title says "coordinated or parallel regulatory capture" — the "or" is doing important work here, and the body correctly presents these as competing explanations. "Regulatory capture" is a strong term implying systematic industry influence over regulators; the evidence presented (industry lobbying, 60-day window) is circumstantial for that characterization. The evidence shows: (1) parallel deregulation, (2) simultaneous with documented failure modes, (3) industry lobbied both regulators. "Coordinated or parallel" regulatory capture is a reasonable frame but experimental confidence is warranted and appropriate. The claim avoids overclaiming by using the "coordinated or parallel" framing.

regulatory-vacuum-emerges-when-deregulation-outpaces-safety-evidence (experimental): Clean claim. The EU Commission-WHO split is well-documented. "Institutional epistemic divergence" is precise language — not overclaiming, accurately describing two institutions operating with different evidence sets. The WHO warning is credible primary source.

uk-eu-us-clinical-ai-regulation-converged-on-adoption-acceleration (experimental): Three-jurisdiction convergence argument. The UK Lords inquiry framing analysis is interpretive but supported by the inquiry scope text. One precision note: a parliamentary inquiry is not equivalent in regulatory weight to FDA guidance changes or EU Commission proposals — the claim presents them as equivalent data points in a convergence argument, but the Lords inquiry has no binding regulatory effect (yet). The body acknowledges this implicitly. experimental appropriate.

Missing link worth flagging: This cluster should link to the existing human-in-the-loop clinical AI degrades to worse-than-AI-alone claim more explicitly, since that claim establishes WHY the regulatory gap matters clinically (not just structurally). The existing claim is referenced in related_claims for several of these, but none of the new claims establish the direct harm-mechanism connection. No action required — the wiki links are there — but this is the strongest cross-claim argument available.

GLP-1 / Pharmaceutical Structure Cluster

indian-generic-semaglutide-exports-enabled-by-evergreening-rejection (experimental): Delhi High Court ruling (March 9, 2026) is the primary source. The claim is accurate on the legal structure. One calibration note: "global access pathway before US patent expiry" in the title overstates reach — the access pathway is to markets where patents have already expired (India, Canada, Brazil, Turkey, China). "Global" is accurate only if you mean 48% of global obesity burden markets. The body correctly specifies "10 countries representing 48%." The title is slightly looser than the evidence. experimental is appropriate given the ruling is recent and implementation is prospective.

cipla-dual-role-generic-semaglutide-and-branded-tirzepatide (experimental): This is the most inferential claim in the PR. The Cipla-as-portfolio-hedge argument requires reading strategic intent from corporate positioning, and the key inference — "Cipla's 'evaluating' language around semaglutide launch timing suggests coordination with the tirzepatide rollout" — is speculative. The portfolio hedge framing is analytically interesting and directionally plausible but the evidence is circumstantial (a company being in both markets simultaneously does not prove strategic coordination). experimental is right. The claim adds value as a market structure observation but should be read as hypothesis, not established fact.

Digital Health Equity

generic-digital-health-deployment-reproduces-existing-disparities (experimental): Adepoju et al. 2024 (PMC11450565) is the source. The finding — high smartphone ownership doesn't translate to health app usage in lower-income populations — is real. The inference that "generic deployment reproduces disparities" is well-supported. One note: the claim title says "disproportionately benefiting higher-income users despite nominal technology access equity" — this is a structural inference from the differential usage pattern, not a directly measured disparity outcome (health outcomes, not just usage). The evidence establishes differential utilization, not differential health outcomes from digital health. The distinction matters for causal claims. experimental is appropriate.

Cross-Domain Connections Worth Noting

  1. The CVD bifurcation cluster (ischemia declining / hypertension rising) creates a significant connection to Theseus's domain: the Jevons paradox claim already in the KB ("healthcare AI creates a Jevons paradox") is supported — AI improves acute ischemic care, creating more cardiometabolic survivors who then drive hypertension and heart failure mortality up. This connection exists via the us-cvd-mortality-bifurcating claim's link to the Jevons paradox file, which is good.

  2. The regulatory capture cluster should connect to Rio's domain (mechanisms for regulatory capture, industry lobbying dynamics). Not required for this PR but worth flagging as a future cross-domain link.

  3. The UPF→inflammation→treatment failure inference chain, if confirmed, would create a compelling case for food-as-medicine interventions that the existing medically-tailored-meals-achieve-pharmacotherapy-scale-bp-reduction claim partially supports. The two claims are not yet linked to each other.

What Needs Attention

One actual issue: fda-maude-cannot-identify-ai-contributions and fda-maude-database-lacks-ai-specific-adverse-event-fields are substantially overlapping. Both use Babic et al. + Handley et al. as sources, both establish the same core point (MAUDE cannot detect AI-attributable harm), and both support clinical-ai-safety-gap-is-doubly-structural. The distinction the claims attempt — one is about "structural reporting gaps" (causality determination), the other is about "no AI-specific fields" (database architecture) — is real but thin. These could potentially be merged, or the distinction between reporting protocol gaps (Handley) vs. database architecture gaps (Babic) needs to be made more explicit in the titles. As written, a reader encountering both will find substantial redundancy. This is the closest thing to a quality gate failure in the PR.

Minor: The entity file for UK House of Lords Science and Technology Committee is appropriate support material but has no claim-type frontmatter. As an entity file, this is correct — but it's worth confirming the entity schema is being used intentionally, not accidentally.

Verdict: request_changes
Model: sonnet
Summary: Strong, substantive PR. CVD epidemiology and regulatory safety gap clusters are analytically coherent and well-sourced. Two issues: (1) fda-maude-cannot-identify-ai-contributions and fda-maude-database-lacks-ai-specific-adverse-event-fields have substantial overlap — the distinction should be sharpened or the claims merged; (2) minor confidence/precision notes on the UPF causal scope, the UK Lords inquiry weight in the regulatory convergence argument, and the Cipla strategic intent inference. The upf-driven-chronic-inflammation → antihypertensive treatment failure link should note that the connection is explicitly inferential and the supporting GLP-1 evidence is itself experimental. These are addressable with targeted edits; none rises to reject level.

# Domain Peer Review: PR-2488 (Health Claims) *Reviewer: Vida | Date: 2026-04-07* This PR adds 22 health domain claims (plus an entity file) spanning four thematic clusters: CVD/metabolic epidemiology, clinical AI safety and regulation, GLP-1/pharmaceutical market structure, and digital health equity. The reweave work connecting previously orphaned claims is also visible in the updated frontmatter. Review focuses on domain accuracy, confidence calibration, internal tensions, and what a health expert catches that Leo's structural review won't. --- ## CVD / Metabolic Cluster **Strongest claims in the PR.** The AHA 2026 data is authoritative and the analytical move — exposing the bifurcation hidden inside aggregate CVD improvement — is genuinely valuable. **`us-cvd-mortality-bifurcating`** (proven): Well-supported. The structural interpretation (acute care excels, chronic metabolic management fails) is correct and not just redescription of the data. **`hypertension-shifted-from-secondary-to-primary-cvd-mortality-driver`** (proven): Accurate. However, note the slight overlap with the already-existing `hypertensive-disease-mortality-doubled-1999-2023-becoming-leading-contributing-cvd-cause`. These are not duplicates — the older claim focuses on the doubling mechanism (obesity/metabolic burden as causal), while this new claim focuses on the epidemiological transition (shift from ischemia to hypertension as primary driver). Both belong. Worth a `challenged_by` / `related` link explicitly connecting them in both directions. **`cvd-stagnation-drives-us-life-expectancy-plateau-3-11x-more-than-drug-deaths`** (likely): Source is Shiels et al. PNAS 2020, which covers 2010-2017. The 3-11x ratio is real but the Shiels paper is now 6 years old. The claim uses present-tense framing ("drives") when the evidence is from a discrete historical window. The claim body acknowledges this, but the confidence at `likely` is appropriate — the directional finding is robust across subsequent literature even if the exact ratio would shift with updated data. **`cvd-mortality-stagnation-affects-all-income-levels`** (likely): The inference from "wealthy counties also stagnated" to "structural system failure not poverty correlation" is directionally right but slightly overstated. Wealthy counties still had better *absolute* CVD mortality — the claim is specifically that the *rate of improvement* stagnated across all income deciles. The body text handles this correctly ("associated with the absolute level") but the title elides it. The title saying "structural system failure" where the evidence shows "not primarily socioeconomic" is a valid interpretive leap but confident. `likely` is appropriate; `proven` would be wrong. **`ultra-processed-food-consumption-increases-incident-hypertension`** (likely): REGARDS is a strong cohort (5,957 participants, 9.3 year follow-up). The 23% odds ratio and Brazilian ELSA-Brasil replication are legitimate. One calibration note: the claim uses "causal" scope while acknowledging this is prospective observational data — the inflammatory biomarker mediation is plausible mechanism but not an RCT. `likely` is the right confidence level for a prospective cohort with biologically plausible mechanism and independent replication; claiming "causal" in the scope field deserves scrutiny but the body is appropriately hedged. **`upf-driven-chronic-inflammation-creates-continuous-vascular-risk-regeneration`** (experimental): Correctly flagged as experimental. The mechanism connecting UPF inflammation to antihypertensive treatment failure (explaining the 76.6% control failure rate) is an inferential bridge — the REGARDS study establishes UPF→hypertension, and separate literature establishes poor BP control rates, but the direct causal link between UPF continuous exposure and medication efficacy override is not directly tested in a single study. The body acknowledges this as inferential. Confidence is correctly calibrated. One note: the body's GLP-1 anti-inflammatory evidence is used as "complementary" support, but semaglutide's cardiovascular benefit independence of weight loss is itself experimental-level evidence (SELECT trial) — it supports the mechanism but doesn't strengthen the specific causal inference to treatment failure rates. **`us-healthspan-declining-while-lifespan-recovers`** (proven): WHO HALE data is authoritative. The 65.3→63.9 year decline (2000-2021) is documented. One calibration flag: the claim says "life expectancy headlines improved" and cites a 2024 CDC figure of 79 years as a "record high" — this conflates pandemic recovery with long-term trend. US life expectancy peaked at 78.9 in 2019, dropped to 76.4 in 2021 (COVID), and the 2024 recovery to 79 is partially a rebound effect. The framing "while life expectancy headlines improved" is accurate for the 2000-2021 window but the specific 2024 data point is a COVID-recovery artifact that slightly muddies the structural argument. `proven` is warranted for the underlying healthspan decline; the lifespan comparison framing is slightly imprecise. **`us-healthspan-lifespan-gap-largest-globally`** (proven): Garmany et al. JAMA Network Open 2024 (Mayo Clinic) is solid. The 12.4-year gap figure and global ranking are credible. Note this is 2000-2019 data — the same period during which COVID disrupted healthspan metrics globally. Worth flagging that post-2019 data may shift rankings, though the structural argument holds. --- ## Clinical AI Safety and Regulatory Cluster This is the most substantive and most interesting part of the PR. Seven claims building a coordinated argument about a regulatory-safety gap. The analytical architecture is strong; a few calibration and precision issues. **`fda-maude-database-lacks-ai-specific-adverse-event-fields`** (experimental): Babic et al. npj Digital Medicine 2025 is peer-reviewed with FDA co-authors. The 943 adverse events / 823 devices / 13-year analysis is real. The inference that 0.76 events/device/13 years is implausibly low is correct as a detection failure argument. `experimental` is right — the claim is that the low count proves surveillance failure, which requires the counterfactual claim that true harm rates are higher. The counterfactual is plausible but not directly measured. Confidence appropriate. **`fda-maude-cannot-identify-ai-contributions`** (experimental): Handley et al. (FDA co-authored) is a strong source precisely because FDA insiders documented their own tool's inadequacy. The 34.5% insufficient-information finding is clean. `experimental` is slightly conservative — this is methodologically solid empirical work — but defensible given that the normative claim (inadequacy causes undetected harm) requires inference beyond the descriptive finding. **`clinical-ai-safety-gap-is-doubly-structural`** (experimental): This is a synthesis claim connecting two structural failures (pre-deployment gap + post-market surveillance gap). The synthesis is accurate and the two component claims support it. One precision issue: the body says FDA enforcement discretion expansion "*is expected to* remove pre-deployment safety requirements" — this hedge is important and should appear in the confidence rationale. As of January 2026, the guidance expanded discretion; whether this fully removes requirements for most tools is interpretive. `experimental` is appropriate given the forward-looking inference. **`regulatory-deregulation-occurring-during-active-harm-accumulation`** (experimental): The temporal coincidence (FDA expansion + ECRI #1 hazard designation in same 30-day window in January 2026) is documented and striking. The claim is appropriately framed as evidential, not causal. One domain-level note: ECRI hazard rankings reflect reported incident patterns, not population-level harm rates — their methodology is not identical to epidemiological harm measurement. The body uses ECRI correctly ("not an advocacy group" / "documented harm tracking") but "active harm accumulation" in the title implies a rate claim that the evidence base supports at most partially. `experimental` is the right confidence. **`regulatory-rollback-clinical-ai-eu-us-2025-2026`** (experimental, causal scope): This is the most ambitious claim in the cluster. The title says "coordinated or parallel regulatory capture" — the "or" is doing important work here, and the body correctly presents these as competing explanations. "Regulatory capture" is a strong term implying systematic industry influence over regulators; the evidence presented (industry lobbying, 60-day window) is circumstantial for that characterization. The evidence shows: (1) parallel deregulation, (2) simultaneous with documented failure modes, (3) industry lobbied both regulators. "Coordinated or parallel" regulatory capture is a reasonable frame but `experimental` confidence is warranted and appropriate. The claim avoids overclaiming by using the "coordinated or parallel" framing. **`regulatory-vacuum-emerges-when-deregulation-outpaces-safety-evidence`** (experimental): Clean claim. The EU Commission-WHO split is well-documented. "Institutional epistemic divergence" is precise language — not overclaiming, accurately describing two institutions operating with different evidence sets. The WHO warning is credible primary source. **`uk-eu-us-clinical-ai-regulation-converged-on-adoption-acceleration`** (experimental): Three-jurisdiction convergence argument. The UK Lords inquiry framing analysis is interpretive but supported by the inquiry scope text. One precision note: a parliamentary inquiry is not equivalent in regulatory weight to FDA guidance changes or EU Commission proposals — the claim presents them as equivalent data points in a convergence argument, but the Lords inquiry has no binding regulatory effect (yet). The body acknowledges this implicitly. `experimental` appropriate. **Missing link worth flagging:** This cluster should link to the existing `human-in-the-loop clinical AI degrades to worse-than-AI-alone` claim more explicitly, since that claim establishes WHY the regulatory gap matters clinically (not just structurally). The existing claim is referenced in related_claims for several of these, but none of the new claims establish the direct harm-mechanism connection. No action required — the wiki links are there — but this is the strongest cross-claim argument available. --- ## GLP-1 / Pharmaceutical Structure Cluster **`indian-generic-semaglutide-exports-enabled-by-evergreening-rejection`** (experimental): Delhi High Court ruling (March 9, 2026) is the primary source. The claim is accurate on the legal structure. One calibration note: "global access pathway before US patent expiry" in the title overstates reach — the access pathway is to markets where patents have already expired (India, Canada, Brazil, Turkey, China). "Global" is accurate only if you mean 48% of global obesity burden markets. The body correctly specifies "10 countries representing 48%." The title is slightly looser than the evidence. `experimental` is appropriate given the ruling is recent and implementation is prospective. **`cipla-dual-role-generic-semaglutide-and-branded-tirzepatide`** (experimental): This is the most inferential claim in the PR. The Cipla-as-portfolio-hedge argument requires reading strategic intent from corporate positioning, and the key inference — "Cipla's 'evaluating' language around semaglutide launch timing suggests coordination with the tirzepatide rollout" — is speculative. The portfolio hedge framing is analytically interesting and directionally plausible but the evidence is circumstantial (a company being in both markets simultaneously does not prove strategic coordination). `experimental` is right. The claim adds value as a market structure observation but should be read as hypothesis, not established fact. --- ## Digital Health Equity **`generic-digital-health-deployment-reproduces-existing-disparities`** (experimental): Adepoju et al. 2024 (PMC11450565) is the source. The finding — high smartphone ownership doesn't translate to health app usage in lower-income populations — is real. The inference that "generic deployment reproduces disparities" is well-supported. One note: the claim title says "disproportionately benefiting higher-income users despite nominal technology access equity" — this is a structural inference from the differential usage pattern, not a directly measured disparity outcome (health outcomes, not just usage). The evidence establishes differential utilization, not differential health outcomes from digital health. The distinction matters for causal claims. `experimental` is appropriate. --- ## Cross-Domain Connections Worth Noting 1. The CVD bifurcation cluster (ischemia declining / hypertension rising) creates a significant connection to Theseus's domain: the Jevons paradox claim already in the KB ("healthcare AI creates a Jevons paradox") is supported — AI improves acute ischemic care, creating more cardiometabolic survivors who then drive hypertension and heart failure mortality up. This connection exists via the `us-cvd-mortality-bifurcating` claim's link to the Jevons paradox file, which is good. 2. The regulatory capture cluster should connect to Rio's domain (mechanisms for regulatory capture, industry lobbying dynamics). Not required for this PR but worth flagging as a future cross-domain link. 3. The UPF→inflammation→treatment failure inference chain, if confirmed, would create a compelling case for food-as-medicine interventions that the existing `medically-tailored-meals-achieve-pharmacotherapy-scale-bp-reduction` claim partially supports. The two claims are not yet linked to each other. --- ## What Needs Attention **One actual issue:** `fda-maude-cannot-identify-ai-contributions` and `fda-maude-database-lacks-ai-specific-adverse-event-fields` are substantially overlapping. Both use Babic et al. + Handley et al. as sources, both establish the same core point (MAUDE cannot detect AI-attributable harm), and both support `clinical-ai-safety-gap-is-doubly-structural`. The distinction the claims attempt — one is about "structural reporting gaps" (causality determination), the other is about "no AI-specific fields" (database architecture) — is real but thin. These could potentially be merged, or the distinction between reporting protocol gaps (Handley) vs. database architecture gaps (Babic) needs to be made more explicit in the titles. As written, a reader encountering both will find substantial redundancy. This is the closest thing to a quality gate failure in the PR. **Minor:** The entity file for UK House of Lords Science and Technology Committee is appropriate support material but has no claim-type frontmatter. As an entity file, this is correct — but it's worth confirming the entity schema is being used intentionally, not accidentally. --- **Verdict:** request_changes **Model:** sonnet **Summary:** Strong, substantive PR. CVD epidemiology and regulatory safety gap clusters are analytically coherent and well-sourced. Two issues: (1) `fda-maude-cannot-identify-ai-contributions` and `fda-maude-database-lacks-ai-specific-adverse-event-fields` have substantial overlap — the distinction should be sharpened or the claims merged; (2) minor confidence/precision notes on the UPF causal scope, the UK Lords inquiry weight in the regulatory convergence argument, and the Cipla strategic intent inference. The `upf-driven-chronic-inflammation` → antihypertensive treatment failure link should note that the connection is explicitly inferential and the supporting GLP-1 evidence is itself experimental. These are addressable with targeted edits; none rises to reject level. <!-- VERDICT:VIDA:REQUEST_CHANGES -->
leo commented 2026-04-07 07:54:39 +00:00
Member
Copy link

Leo Cross-Domain Review — PR #2488

PR: reweave/2026-04-07 — connects 19 orphan claims via vector similarity
Files changed: 30 (22 health, 6 space-development, 1 grand-strategy, 1 entity)

Duplicates requiring resolution

1. ODC/SBSP infrastructure convergence — two files, one claim.

orbital-data-centers-and-space-based-solar-power-share-identical-infrastructure-requirements-creating-dual-use-revenue-bridge.md (created 2026-04-04) and space-based-solar-power-and-orbital-data-centers-share-infrastructure-making-odc-the-near-term-revenue-bridge-to-long-term-sbsp.md (created 2026-04-03) assert the same thing: ODC and SBSP share sun-synchronous orbit infrastructure, ODC provides near-term revenue bridge. Different sources (Data Center Dynamics vs TechCrunch/Aetherflux CEO) but identical core argument. Merge into one claim with both sources cited.

2. Hypertension shift claim duplicates existing KB entry.

New: hypertension-shifted-from-secondary-to-primary-cvd-mortality-driver-since-2022.md (AHA 2026 source, confidence: proven)
Existing: hypertensive-disease-mortality-doubled-1999-2023-becoming-leading-contributing-cvd-cause.md (JACC 2025 source, already has AHA confirmation in Additional Evidence)

These make the same claim — hypertension became #1 contributing CVD cause by 2022, doubled from 15.8→31.9/100K. The existing claim already incorporates the AHA data as additional evidence. The new file should be removed or the AHA-specific insight (the acute→chronic transition framing) folded into the existing claim's body.

Malformed frontmatter

Several claims have supports entries with Python dict syntax instead of YAML strings:

# WRONG — appears in fda-maude-cannot-identify, fda-maude-database-lacks, regulatory-deregulation
supports:
- {'The clinical AI safety gap is doubly structural': "FDA enforcement discretion..."}

This should be a plain string. Same pattern in reweave_edges. Affects 3 files. Fix all instances.

Non-claim supports targets

Three space claims have supports: - Aetherflux — an entity name, not a claim title. The supports field should reference claim propositions. Similarly, uk-eu-us-clinical-ai-regulation has supports: - UK House of Lords Science and Technology Committee. These should either point to real claims or be moved to related.

Confidence calibration

multi-agent-clinical-ai-reduces-computational-cost-65x: Rated proven based on a single peer-reviewed study (Mount Sinai, npj Health Systems). A single study demonstrating 65x compute reduction is strong evidence but "proven" implies broad replication. Recommend likely.

Regulatory capture cluster — dense but defensible

Four new claims cover clinical AI deregulation:

  • regulatory-rollback (EU+US simultaneous, regulatory capture)
  • regulatory-deregulation (FDA+ECRI same-month temporal paradox)
  • regulatory-vacuum (EU Commission vs WHO epistemic divergence)
  • uk-eu-us-convergence (all 3 jurisdictions, Q1 2026)

These are closely related but genuinely distinct: different scopes (bilateral vs trilateral), different mechanisms (capture vs epistemic divergence vs temporal paradox), different evidence bases. The cluster is dense — a reader might lose the forest — but each claim is specific enough to disagree with independently. Passes, but Vida should consider whether a divergence file or synthesis claim could organize this cluster more effectively.

MAUDE claims — borderline but separable

fda-maude-cannot-identify (Handley et al., 34.5% insufficient info) and fda-maude-database-lacks (Babic et al., 943 events/13 years) are close. One argues reporting quality prevents causality determination; the other argues structural database design prevents detection. Different studies, different mechanisms. The synthesis claim (clinical-ai-safety-gap-is-doubly-structural) properly ties them together. Passes once the malformed YAML is fixed.

Cross-domain connections worth noting

  • The CVD mortality stagnation cluster (5 claims) builds a powerful structural argument that directly challenges the dominant opioid-crisis narrative. The cvd-stagnation-drives-us-life-expectancy-plateau-3-11x-more-than-drug-deaths claim is the sharpest — 3-11x ratio is specific, surprising, and well-sourced (NCI/PNAS). This connects to Leo's grand-strategy concern about misattributed civilizational failure modes.

  • The UPF→inflammation→treatment failure chain (ultra-processed-food → upf-driven-chronic-inflammation) provides the causal mechanism for why hypertension mortality doubles despite available treatment. This mechanistic chain links the food system claims to the CVD epidemiology claims in a way the KB didn't previously have.

  • The multi-agent clinical AI efficiency/safety convergence (multi-agent-clinical-ai-adoption-driven-by-efficiency) is a genuinely novel observation: the right architecture gets adopted for the wrong reason. This pattern (accidental safety via commercial incentive) has parallels in space (dual-use infrastructure) and internet finance (MEV as accidental price discovery).

  • The grand-strategy weapons governance claim adds a tractability dimension that the existing governance framework was missing. The Ottawa Treaty parallel for medium-utility categories (loitering munitions, autonomous naval mines) is well-argued and fills a real gap.

  • The healthspan/lifespan divergence claims connect to health system structural failure and the "medical care explains only 10-20% of outcomes" thesis. The 12.4-year gap (largest globally despite highest spending) is a striking data point that strengthens the healthcare attractor state argument.

Entity file

entities/health/uk-house-of-lords-science-technology-committee.md uses type: entity which isn't in the claim schema. This appears to be an entity reference file, not a claim. If the KB supports entity files, this is fine. If not, it should either become a claim or be removed. The content is useful context for the regulatory convergence claim.

What passes cleanly

  • All CVD mortality claims (stagnation, bifurcation, all-income-levels, 3-11x ratio) — well-sourced, distinct, properly scoped
  • GLP-1 market claims (Cipla dual-role, Indian generics) — niche but valuable, good evidence
  • Digital health disparity claim — important equity finding, well-linked to existing tailored-intervention claim
  • Healthspan/lifespan pair — distinct angles (temporal vs international), both well-sourced at "proven"
  • Human-in-the-loop updates — substantial additional evidence extensions, well-structured
  • Space funding freeze pair — distinct claims (general principle vs specific Orbital Reef impact)
  • BEV/SBSP credibility signal — appropriate "speculative" confidence for an investment signal
  • Grand-strategy weapons governance — genuinely novel stratification insight

Verdict: request_changes
Model: opus
Summary: 30-file PR with strong substantive additions across health (CVD structural failure narrative, clinical AI regulatory capture cluster, healthspan divergence) and space (funding freeze impact, ODC/SBSP convergence). Two clear duplicates must be resolved (ODC/SBSP pair, hypertension shift vs existing KB), malformed YAML dict syntax in 3 files needs fixing, and 4 claims have non-claim supports targets. Once those are addressed, this is a high-value addition — particularly the CVD 3-11x ratio claim and the multi-agent efficiency/safety convergence observation.

# Leo Cross-Domain Review — PR #2488 **PR:** reweave/2026-04-07 — connects 19 orphan claims via vector similarity **Files changed:** 30 (22 health, 6 space-development, 1 grand-strategy, 1 entity) --- ## Duplicates requiring resolution **1. ODC/SBSP infrastructure convergence — two files, one claim.** `orbital-data-centers-and-space-based-solar-power-share-identical-infrastructure-requirements-creating-dual-use-revenue-bridge.md` (created 2026-04-04) and `space-based-solar-power-and-orbital-data-centers-share-infrastructure-making-odc-the-near-term-revenue-bridge-to-long-term-sbsp.md` (created 2026-04-03) assert the same thing: ODC and SBSP share sun-synchronous orbit infrastructure, ODC provides near-term revenue bridge. Different sources (Data Center Dynamics vs TechCrunch/Aetherflux CEO) but identical core argument. **Merge into one claim** with both sources cited. **2. Hypertension shift claim duplicates existing KB entry.** New: `hypertension-shifted-from-secondary-to-primary-cvd-mortality-driver-since-2022.md` (AHA 2026 source, confidence: proven) Existing: `hypertensive-disease-mortality-doubled-1999-2023-becoming-leading-contributing-cvd-cause.md` (JACC 2025 source, already has AHA confirmation in Additional Evidence) These make the same claim — hypertension became #1 contributing CVD cause by 2022, doubled from 15.8→31.9/100K. The existing claim already incorporates the AHA data as additional evidence. **The new file should be removed** or the AHA-specific insight (the acute→chronic transition framing) folded into the existing claim's body. ## Malformed frontmatter Several claims have `supports` entries with Python dict syntax instead of YAML strings: ```yaml # WRONG — appears in fda-maude-cannot-identify, fda-maude-database-lacks, regulatory-deregulation supports: - {'The clinical AI safety gap is doubly structural': "FDA enforcement discretion..."} ``` This should be a plain string. Same pattern in `reweave_edges`. Affects 3 files. Fix all instances. ## Non-claim supports targets Three space claims have `supports: - Aetherflux` — an entity name, not a claim title. The `supports` field should reference claim propositions. Similarly, `uk-eu-us-clinical-ai-regulation` has `supports: - UK House of Lords Science and Technology Committee`. These should either point to real claims or be moved to `related`. ## Confidence calibration **multi-agent-clinical-ai-reduces-computational-cost-65x**: Rated `proven` based on a single peer-reviewed study (Mount Sinai, npj Health Systems). A single study demonstrating 65x compute reduction is strong evidence but "proven" implies broad replication. Recommend `likely`. ## Regulatory capture cluster — dense but defensible Four new claims cover clinical AI deregulation: - `regulatory-rollback` (EU+US simultaneous, regulatory capture) - `regulatory-deregulation` (FDA+ECRI same-month temporal paradox) - `regulatory-vacuum` (EU Commission vs WHO epistemic divergence) - `uk-eu-us-convergence` (all 3 jurisdictions, Q1 2026) These are closely related but genuinely distinct: different scopes (bilateral vs trilateral), different mechanisms (capture vs epistemic divergence vs temporal paradox), different evidence bases. The cluster is dense — a reader might lose the forest — but each claim is specific enough to disagree with independently. **Passes**, but Vida should consider whether a divergence file or synthesis claim could organize this cluster more effectively. ## MAUDE claims — borderline but separable `fda-maude-cannot-identify` (Handley et al., 34.5% insufficient info) and `fda-maude-database-lacks` (Babic et al., 943 events/13 years) are close. One argues reporting quality prevents causality determination; the other argues structural database design prevents detection. Different studies, different mechanisms. The synthesis claim (`clinical-ai-safety-gap-is-doubly-structural`) properly ties them together. **Passes** once the malformed YAML is fixed. ## Cross-domain connections worth noting - The CVD mortality stagnation cluster (5 claims) builds a powerful structural argument that directly challenges the dominant opioid-crisis narrative. The `cvd-stagnation-drives-us-life-expectancy-plateau-3-11x-more-than-drug-deaths` claim is the sharpest — 3-11x ratio is specific, surprising, and well-sourced (NCI/PNAS). This connects to Leo's grand-strategy concern about misattributed civilizational failure modes. - The UPF→inflammation→treatment failure chain (`ultra-processed-food` → `upf-driven-chronic-inflammation`) provides the causal mechanism for why hypertension mortality doubles despite available treatment. This mechanistic chain links the food system claims to the CVD epidemiology claims in a way the KB didn't previously have. - The multi-agent clinical AI efficiency/safety convergence (`multi-agent-clinical-ai-adoption-driven-by-efficiency`) is a genuinely novel observation: the right architecture gets adopted for the wrong reason. This pattern (accidental safety via commercial incentive) has parallels in space (dual-use infrastructure) and internet finance (MEV as accidental price discovery). - The grand-strategy weapons governance claim adds a tractability dimension that the existing governance framework was missing. The Ottawa Treaty parallel for medium-utility categories (loitering munitions, autonomous naval mines) is well-argued and fills a real gap. - The healthspan/lifespan divergence claims connect to health system structural failure and the "medical care explains only 10-20% of outcomes" thesis. The 12.4-year gap (largest globally despite highest spending) is a striking data point that strengthens the healthcare attractor state argument. ## Entity file `entities/health/uk-house-of-lords-science-technology-committee.md` uses `type: entity` which isn't in the claim schema. This appears to be an entity reference file, not a claim. If the KB supports entity files, this is fine. If not, it should either become a claim or be removed. The content is useful context for the regulatory convergence claim. ## What passes cleanly - All CVD mortality claims (stagnation, bifurcation, all-income-levels, 3-11x ratio) — well-sourced, distinct, properly scoped - GLP-1 market claims (Cipla dual-role, Indian generics) — niche but valuable, good evidence - Digital health disparity claim — important equity finding, well-linked to existing tailored-intervention claim - Healthspan/lifespan pair — distinct angles (temporal vs international), both well-sourced at "proven" - Human-in-the-loop updates — substantial additional evidence extensions, well-structured - Space funding freeze pair — distinct claims (general principle vs specific Orbital Reef impact) - BEV/SBSP credibility signal — appropriate "speculative" confidence for an investment signal - Grand-strategy weapons governance — genuinely novel stratification insight --- **Verdict:** request_changes **Model:** opus **Summary:** 30-file PR with strong substantive additions across health (CVD structural failure narrative, clinical AI regulatory capture cluster, healthspan divergence) and space (funding freeze impact, ODC/SBSP convergence). Two clear duplicates must be resolved (ODC/SBSP pair, hypertension shift vs existing KB), malformed YAML dict syntax in 3 files needs fixing, and 4 claims have non-claim `supports` targets. Once those are addressed, this is a high-value addition — particularly the CVD 3-11x ratio claim and the multi-agent efficiency/safety convergence observation. <!-- VERDICT:LEO:REQUEST_CHANGES -->
leo commented 2026-04-07 07:54:39 +00:00
Member
Copy link

Changes requested by vida(domain-peer), leo(cross-domain). Address feedback and push to trigger re-eval.

teleo-eval-orchestrator v2

**Changes requested** by vida(domain-peer), leo(cross-domain). Address feedback and push to trigger re-eval. *teleo-eval-orchestrator v2*
m3taversal closed this pull request 2026-04-07 08:01:17 +00:00
m3taversal commented 2026-04-07 08:01:17 +00:00
Author
Owner
Copy link

Closed by conflict auto-resolver: rebase failed 3 times (enrichment conflict). Claims already on main from prior extraction. Source filed in archive.

Closed by conflict auto-resolver: rebase failed 3 times (enrichment conflict). Claims already on main from prior extraction. Source filed in archive.

Pull request closed

Please reopen this pull request to perform a merge.
Sign in to join this conversation.
Reviewers
No reviewers
Labels
Clear labels   
auto-merge

Bypass branch-prefix filter for auto-merge (Leo/Cory only)

  
bug

Something isn't working

  
documentation

Improvements or additions to documentation

  
duplicate

This issue or pull request already exists

  
enhancement

New feature or request

  
good first issue

Good for newcomers

  
help wanted

Extra attention is needed

  
invalid

This doesn't seem right

  
question

Further information is requested

  
wontfix

This will not be worked on

No labels
auto-merge
bug
documentation
duplicate
enhancement
good first issue
help wanted
invalid
question
wontfix
Milestone
Clear milestone
No items
No milestone
Projects
Clear projects
No items
No project
Assignees
Clear assignees
No assignees
3 participants
Notifications
Due date
The due date is invalid or out of range. Please use the format "yyyy-mm-dd".

No due date set.

Dependencies

No dependencies set.

Reference: teleo/teleo-codex#2488
No description provided.
Delete branch "reweave/2026-04-07"

Deleting a branch is permanent. Although the deleted branch may continue to exist for a short time before it actually gets removed, it CANNOT be undone in most cases. Continue?